» Articles » PMID: 35935176

Neurological Manifestations by Sex and Age Group in COVID-19 Inhospital Patients

Abstract

Introduction: Neurological manifestations have been associated with a poorer prognosis in COVID-19. However, data regarding their incidence according to sex and age groups is still lacking.

Methods: This retrospective multicentric cohort collected data from 39 Brazilian hospitals from 17 cities, from adult COVID-19 admitted from March 2020 to January 2022. Neurological manifestations presented at hospital admission were assessed according to incidence by sex and age group.

Results: From 13,603 COVID-19 patients, median age was 60 years old and 53.0% were men. Women were more likely to present with headaches (22.4% vs. 17.7%,  < 0.001; OR 1.36, 95% confidence interval [CI] 1.22-1.52) than men and also presented a lower risk of having seizures (OR 0.43, 95% CI 0.20-0.94). Although delirium was more frequent in women (6.6% vs. 5.7%,  = 0.020), sex was not associated with delirium in the multivariable logistc regresssion analysis. Delirium, syncope and coma increased with age (1.5% [18-39 years] vs. 22.4% [80 years or over], p < 0.001, OR 1.07, 95% CI 1.06-1.07; 0.7% vs. 1.7%,  = 0.002, OR 1.01, 95% CI 1.00-1.02; 0.2% vs. 1.3% p < 0.001, OR 1.04, 95% CI 1.02-1.06), while, headache (26.5% vs. 7.1%, OR 0.98, 95% CI 0.98-0.99), anosmia (11.4% vs. 3.3%, OR 0.99, 95% CI] 0.98-0.99 and ageusia (13.1% vs. 3.5%, OR 0.99, CI 0.98-0.99) decreased (p < 0.001 for all).

Conclusion: Older COVID-19 patients were more likely to present delirium, syncope and coma, while the incidence of anosmia, ageusia and headaches decreased with age. Women were more likely to present headache, and less likely to present seizures.

Citing Articles

Neurological risks of COVID-19 in women: the complex immunology underpinning sex differences.

Gu J, Zhang J, Liu Q, Xu S Front Immunol. 2023; 14:1281310.

PMID: 38035090 PMC: 10685449. DOI: 10.3389/fimmu.2023.1281310.


A suitable model to investigate acute neurological consequences of coronavirus infection.

Pimenta J, Oliveira B, Lima A, Machado C, Lacerda L, Rossi L Inflamm Res. 2023; 72(10-11):2073-2088.

PMID: 37837557 DOI: 10.1007/s00011-023-01798-w.


Clinical profile, treatment, and outcomes of patients with COVID-19 in a tertiary referral hospital in South Sumatera, Indonesia: A retrospective single-center study.

Marteka D, Malik A, Faustine I, Syafhan N Belitung Nurs J. 2023; 8(6):529-537.

PMID: 37554231 PMC: 10405660. DOI: 10.33546/bnj.2302.

References
1.
Kumar D, Jahan S, Khan A, Siddiqui A, Redhu N, Wahajuddin . Neurological Manifestation of SARS-CoV-2 Induced Inflammation and Possible Therapeutic Strategies Against COVID-19. Mol Neurobiol. 2021; 58(7):3417-3434. PMC: 7955900. DOI: 10.1007/s12035-021-02318-9. View

2.
Rebora P, Rozzini R, Bianchetti A, Blangiardo P, Marchegiani A, Piazzoli A . Delirium in Patients with SARS-CoV-2 Infection: A Multicenter Study. J Am Geriatr Soc. 2021; 69(2):293-299. PMC: 7753490. DOI: 10.1111/jgs.16969. View

3.
Garcia-Azorin D, Layos-Romero A, Porta-Etessam J, Membrilla J, Caronna E, Gonzalez-Martinez A . Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients. Cephalalgia. 2022; 42(8):804-809. DOI: 10.1177/03331024211068074. View

4.
Porta-Etessam J, Nunez-Gil I, Gonzalez Garcia N, Fernandez-Perez C, Viana-Llamas M, Maroun Eid C . COVID-19 anosmia and gustatory symptoms as a prognosis factor: a subanalysis of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry. Infection. 2021; 49(4):677-684. PMC: 7917537. DOI: 10.1007/s15010-021-01587-9. View

5.
Johansson A, Mohamed M, Moulin T, Schioth H . Neurological manifestations of COVID-19: A comprehensive literature review and discussion of mechanisms. J Neuroimmunol. 2021; 358:577658. PMC: 8272134. DOI: 10.1016/j.jneuroim.2021.577658. View